ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Kiniksa Pharmaceuticals (UK), Ltd

Kiniksa Pharmaceuticals (UK), Ltd is an active company incorporated on 6 December 2018 with the registered office located in London, Greater London. Kiniksa Pharmaceuticals (UK), Ltd was registered 7 years ago.
Status
Active
Active since incorporation
Company No
11716038
Private limited company
Age
7 years
Incorporated 6 December 2018
Size
Large
Turnover is over £54M
Balance sheet is over £27M
Confirmation
Submitted
Dated 14 November 2025 (23 days ago)
Next confirmation dated 14 November 2026
Due by 28 November 2026 (11 months remaining)
Last change occurred 12 months ago
Accounts
Submitted
For period 1 Jan31 Dec 2024 (1 year)
Accounts type is Audit Exemption Subsidiary
Next accounts for period 31 December 2025
Due by 30 September 2026 (9 months remaining)
Address
105 Piccadilly, Second Floor
London
W1J 7NJ
England
Address changed on 28 Nov 2025 (9 days ago)
Previous address was 105 Piccadilly 105 Piccadilly Second Floor London W1J 7NJ England
Telephone
Unreported
Email
Unreported
People
Officers
3
Shareholders
1
Controllers (PSC)
1
Director • American • Lives in United States • Born in Apr 1974
Director • British • Lives in England • Born in Jun 1981
Secretary
Kiniksa Pharmaceuticals International, Plc
PSC
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
No mutual companies found
Financials
Net Assets, Total Assets & Total Liabilities (2019–2024)
Period Ended
31 Dec 2024
For period 31 Dec31 Dec 2024
Traded for 12 months
Cash in Bank
£99.92M
Increased by £45.22M (+83%)
Turnover
£344.32M
Increased by £131.4M (+62%)
Employees
13
Increased by 1 (+8%)
Total Assets
£799.96M
Increased by £26.4M (+3%)
Total Liabilities
-£105.11M
Increased by £39.17M (+59%)
Net Assets
£694.86M
Decreased by £12.77M (-2%)
Debt Ratio (%)
13%
Increased by 4.62% (+54%)
Latest Activity
Registered Address Changed
9 Days Ago on 28 Nov 2025
Mr Mark Anthony Ragosa Details Changed
20 Days Ago on 17 Nov 2025
Confirmation Submitted
23 Days Ago on 14 Nov 2025
Registered Address Changed
1 Month Ago on 4 Nov 2025
Registered Address Changed
1 Month Ago on 4 Nov 2025
Subsidiary Accounts Submitted
2 Months Ago on 27 Sep 2025
Madelyn Demsky Zeylikman Resigned
2 Months Ago on 17 Sep 2025
Mr Douglas Barry Appointed
2 Months Ago on 17 Sep 2025
Adam William Burgess Resigned
2 Months Ago on 12 Sep 2025
Confirmation Submitted
12 Months Ago on 9 Dec 2024
Get Credit Report
Discover Kiniksa Pharmaceuticals (UK), Ltd's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Registered office address changed from 105 Piccadilly 105 Piccadilly Second Floor London W1J 7NJ England to 105 Piccadilly, Second Floor London W1J 7NJ on 28 November 2025
Submitted on 28 Nov 2025
Director's details changed for Mr Mark Anthony Ragosa on 17 November 2025
Submitted on 28 Nov 2025
Confirmation statement made on 14 November 2025 with no updates
Submitted on 14 Nov 2025
Registered office address changed from Kiniksa Pharmaceuticals (Uk) Ltd, Third Floor, 23 Old Bond Street London W1S 4PZ United Kingdom to 105 Piccadilly 105 Piccadilly London W1J 7NJ on 4 November 2025
Submitted on 4 Nov 2025
Registered office address changed from 105 Piccadilly 105 Piccadilly London W1J 7NJ England to 105 Piccadilly 105 Piccadilly Second Floor London W1J 7NJ on 4 November 2025
Submitted on 4 Nov 2025
Notice of agreement to exemption from audit of accounts for period ending 31/12/24
Submitted on 27 Sep 2025
Audit exemption statement of guarantee by parent company for period ending 31/12/24
Submitted on 27 Sep 2025
Consolidated accounts of parent company for subsidiary company period ending 31/12/24
Submitted on 27 Sep 2025
Audit exemption subsidiary accounts made up to 31 December 2024
Submitted on 27 Sep 2025
Appointment of Mr Douglas Barry as a secretary on 17 September 2025
Submitted on 17 Sep 2025
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year